Arvind Agrawal has more than 20 years of experience in medical affairs and clinical development. Prior to Opiant, he was Head of Medical Affairs and New Products at Mundipharma International, where he made significant advances towards the development of a novel treatment for opioid addiction. Before that, while acting as European Clinical and Scientific Affairs Director at Reckitt Benckiser Pharmaceuticals, he developed strategies leading to positive clinical, political, and legislative changes for the treatment of opioid dependence. His earlier professional experience included various senior management positions in medical affairs and clinical development at: AstraZeneca plc, GlaxoSmithKline plc, SmithKline Beecham plc, and Wellcome Pharmaceuticals. There he was instrumental in launching the pharmaceutical blockbusters Crestor (rosuvastatin) and Avandia (rosiglitazone). Currently, he is the Managing Director of Ekagra Ltd, a pharmaceutical medical affairs consultancy in the U.K. Mr. Agrawal holds a BSc (Hons) in Physiology from University College and an MSc in Human & Applied Physiology from King’s College, University of London.